Criteria for the accurate interpretation of changes in left ventricular ejection fraction and cardiac volumes as assessed by rest and exercise gated radionuclide angiography

Beta-blockers for congestive heart failure in children

BACKGROUND

Beta-blockers are an essential part of standard therapy in adult congestive heart failure and therefore, are expected to be beneficial in children. However, congestive heart failure in children differs from that in adults in terms of characteristics, aetiology, and drug clearance. Therefore, paediatric needs must be specifically investigated. This is an update of a Cochrane review previously published in 2009.

OBJECTIVES

To assess the effect of beta-adrenoceptor-blockers (beta-blockers) in children with congestive heart failure.

SEARCH METHODS

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and LILACS up to November 2015. Bibliographies of identified studies were checked. No language restrictions were applied.

SELECTION CRITERIA

Randomised, controlled, clinical trials investigating the effect of beta-blocker therapy on paediatric congestive heart failure.

DATA COLLECTION AND ANALYSIS

Two review authors independently extracted and assessed data from the included trials.

MAIN RESULTS

We identified four new studies for the review update; the review now includes seven studies with 420 participants. Four small studies with 20 to 30 children each, and two larger studies of 80 children each, showed an improvement of congestive heart failure with beta-blocker therapy. A larger study with 161 participants showed no evidence of benefit over placebo in a composite measure of heart failure outcomes. The included studies showed no significant difference in mortality or heart transplantation rates between the beta-blocker and control groups. No significant adverse events were reported with beta-blockers, apart from one episode of complete heart block. A meta-analysis of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) data showed a very small improvement with beta-blockers. However, there were vast differences in the age, age range, and health of the participants (aetiology and severity of heart failure; heterogeneity of diagnoses and co-morbidities); there was a range of treatments across studies (choice of beta-blocker, dosing, duration of treatment); and a lack of standardised methods and outcome measures. Therefore, the primary outcomes could not be pooled in meta-analyses.

AUTHORS' CONCLUSIONS

There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme. However, the sparse data available suggested that children with congestive heart failure might benefit from beta-blocker treatment. Further investigations in clearly defined populations with standardised methodology are required to establish guidelines for therapy. Pharmacokinetic investigations of beta-blockers in children are also required to provide effective dosing in future trials.

The Relationship Between Bone Mineral Density and Cardiovascular Function in Duchenne Muscular Dystrophy: A Retrospective Cohort Study

INTRODUCTION:

Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder that causes progressive skeletal and cardiac muscle weakness in boys. Cardiac dysfunction is a frequent cause of death in DMD. Glucocorticoids are the standard of care in DMD. The long-term use of oral glucocorticoids in DMD is complicated by poor bone health. Epidemiological studies suggest a biological link between the loss of bone mineral density (BMD) and cardiovascular disease, including coronary artery and cerebrovascular diseases. Whether an association between low BMD and cardiac dysfunction occurs in DMD boys has not yet been studied. The objective of this retrospective cohort study was to examine the relationship between BMD and cardiovascular health in DMD.

METHODS:

Retrospective data analyses was performed from de-identified medical records from a tertiary academic medical center. Whole body BMD was measured using dual-energy xray absorptiometry (DEXA) scan and left ventricular ejection fraction (LVEF) was measured using echocardiogram. Linear regression was used to evaluate the relationship between BMD and LVEF.

RESULTS:

Data was analyzed from a total of 32 boys with DMD. The mean age at which baseline BMD measurements was obtained of 11±3 (SD) years. The worst LVEF was measured at a mean of 23.7±21.8 (SD) months after the baseline BMD measurement. The final adjusted linear regression of the relationship between baseline BMD z-score and worst LVEF was not statistically significant (ß=0.41, p‑value=0.6455).

DISCUSSION:

In this cohort of boys with DMD, BMD was not associated with LVEF dysfunction up to 79 months later. Future research with a longer longitudinal follow-up period is warranted to evaluate the relationship between BMD and cardiovascular disease in DMD.

Radiation reduction and faster acquisition times with SPECT gated blood pool scans using a high-efficiency cardiac SPECT camera

BACKGROUND

Planar gated blood pool scans are an established method for the evaluation of left ventricular ejection fraction (LVEF) but the camera technology used for these studies has not significantly changed in decades. The purpose of this study was to determine the diagnostic accuracy of new high-efficiency SPECT gated blood pool scans compared to traditional scans and determine if they can be performed with lower radiation doses or faster acquisition times.

METHODS

Patients undergoing a planar gated blood pool scan on a Na-I SPECT camera who consented to participate were subsequently imaged for 5 minutes in "List Mode" using a high-efficiency SPECT camera. LVEF was calculated for both the planar study and at 1, 2, 3, 4, and 5 minutes of acquisition on the high-efficiency camera. Counts acquired in the field of view, counts in the cardiac blood pool and LVEF were compared.

RESULTS

A total of 46 patients were analyzed (48% male, mean age 55 years, and BMI 27.6 kg/m(2)) who received an average Tc-99m dose of 20.3 mCi (5.3 mSv), 17 (37%) with abnormal LVEF's. The Na-I camera averaged 24,514 counts/min/mCi in the field of view and 8662 counts/min/mCi in the cardiac blood pool while the high-efficiency camera averaged 65,219 counts/min/mCi and 41,427 counts/min/mCi, respectively. Compared to the planar calculation of LVEF, 1-minute SPECT LVEF was on average 8.6 ± 10.7 higher, 2 minutes 3.5 ± 7.6 higher, 3 minutes 2.9 ± 8.5 higher, 4 minutes 2.5 ± 7.0 higher, and 5 minutes 1.1 ± 6.2 higher. Good correlation was seen between the SPECT LVEF's and the planar LVEF's across all acquisition times with correlation coefficients of 0.74-0.93.

CONCLUSIONS

High-efficiency SPECT technology can reduce radiation exposure to patients during gated blood pool imaging or decrease acquisition time while maintaining diagnostic accuracy. Based on the improved count sensitivity with high-efficiency SPECT, a 50% reduction in injected activity may be achievable while maintaining short imaging times of 5 minutes, with further reduction possible at longer imaging times.

Beta-blockers for congestive heart failure in children

BACKGROUND

Beta-blockers are an essential part of standard therapy in adult congestive heart failure and therefore, are expected to be beneficial in children. However, congestive heart failure in children differs from that in adults in terms of characteristics, aetiology, and drug clearance. Therefore, paediatric needs must be specifically investigated. This is an update of a Cochrane review previously published in 2009.

OBJECTIVES

To assess the effect of beta-adrenoceptor-blockers (beta-blockers) in children with congestive heart failure.

SEARCH METHODS

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and LILACS up to November 2015. Bibliographies of identified studies were checked. No language restrictions were applied.

SELECTION CRITERIA

Randomised, controlled, clinical trials investigating the effect of beta-blocker therapy on paediatric congestive heart failure.

DATA COLLECTION AND ANALYSIS

Two review authors independently extracted and assessed data from the included trials.

MAIN RESULTS

We identified four new studies for the review update; the review now includes seven studies with 420 participants. Four small studies with 20 to 30 children each, and two larger studies of 80 children each, showed an improvement of congestive heart failure with beta-blocker therapy. A larger study with 161 participants showed no evidence of benefit over placebo in a composite measure of heart failure outcomes. The included studies showed no significant difference in mortality or heart transplantation rates between the beta-blocker and control groups. No significant adverse events were reported with beta-blockers, apart from one episode of complete heart block. A meta-analysis of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) data showed a very small improvement with beta-blockers.However, there were vast differences in the age, age range, and health of the participants (aetiology and severity of heart failure; heterogeneity of diagnoses and co-morbidities); there was a range of treatments across studies (choice of beta-blocker, dosing, duration of treatment); and a lack of standardised methods and outcome measures. Therefore, the primary outcomes could not be pooled in meta-analyses.

AUTHORS' CONCLUSIONS

There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme. However, the sparse data available suggested that children with congestive heart failure might benefit from beta-blocker treatment. Further investigations in clearly defined populations with standardised methodology are required to establish guidelines for therapy. Pharmacokinetic investigations of beta-blockers in children are also required to provide effective dosing in future trials.

A prospective evaluation of the repeatability of left ventricular ejection fraction measurement by gated SPECT

BACKGROUND

Gated single-photon emission computed tomography (SPECT) is widely used for myocardial perfusion imaging and provides an automated assessment of left ventricular ejection fraction (LVEF). We prospectively tested the repeatability of serial SPECT-derived LVEF. This information is essential in order to inform the interpretation of a change in LV function on serial testing.

METHODS

Consenting patients (n = 50) from among those referred for clinically indicated gated myocardial perfusion SPECT (MPs) were recruited. Following the clinical rest-stress study, patients were repositioned on the camera table for a second acquisition using identical parameters. Patient positioning, image acquisition and processing for the second scan were independently performed by a technologist blinded to the clinical scan. Quantitative LVEF was generated by Quantitative Gated SPECT and recorded as EF1 and EF2, respectively. Repeatability of serial results was assessed using the Bland-Altman method. The limits of repeatability and repeatability coefficients were generated to determine the maximum variation in LVEF that can be expected to result from test variability. Repeatability was tested across a broad range of LV systolic function and myocardial perfusion.

RESULTS

The mean difference between EF1 and EF2 was 1.6% (EF units), with 95% limits of repeatability of +9.1% to -6.0% (repeatability coefficient 7.5%). Correlation between serial EF measurements was excellent (r = 0.9809). Similar results were obtained in subgroups based on normal or abnormal EF and myocardial perfusion. The largest repeatability coefficient of 8.1% was seen in patients with abnormal LV systolic function.

CONCLUSION

When test protocol and acquisition parameters are kept constant, a difference of >8% EF units on serial MPs is indicative of a true change 95% of the time.

Comparison of interstudy reproducibility of equilibrium electrocardiography-gated SPECT radionuclide angiography versus planar radionuclide angiography for the quantification of global left ventricular function

BACKGROUND

Electrocardiography-gated single photon emission computed tomography (SPECT) radionuclide angiography (RNA) provides accurate measurement of both left ventricular (LV) ejection fraction (EF) and end-diastolic and end-systolic volumes. In this study we studied the interstudy precision and reliability of SPECT RNA as compared with planar RNA for the measurement of global systolic LV function.

METHODS AND RESULTS

The population included 10 patients with chronic coronary artery disease having 2 sets of acquisitions, each consisting of planar and SPECT RNA. SPECT RNA was processed with SPECT-QBS and SPECT-35%. (For SPECT-35%, a manual segmentation method based on the 35% threshold of the maximum LV cavity activity is used to provide estimates of the number of voxels and the activity included in the LV cavity. The calculated LV number of voxels is then used to calculate LV volume measurement. The LV EF is calculated as the ratio of LV end-diastolic and end-systolic activity.) For LV EF, end-diastolic volume, and end-systolic volume, the interstudy precision, as reflected by the correlation coefficient, coefficient of variability, coefficient of repeatability, and within-subject coefficient of variation, and the interstudy reliability, as reflected by the intraclass correlation coefficient, were best with SPECT-35%, followed by planar RNA and then SPECT-QBS, respectively. The sample size needed to objectify a change in a parameter of LV function is lowest with SPECT-35%, followed by planar RNA and then SPECT-QBS, respectively.

CONCLUSIONS

The SPECT-35% processing method provides excellent interstudy precision and reliability for LV function measurement. In this aspect it seems to be better than planar RNA and SPECT-QBS. These results need to be confirmed in a larger patient population.

Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial

BACKGROUND

Nitrates are widely used in the treatment of angina in patients with acute myocardial infarction (AMI). Short-term administration prevents left ventricular (LV) dilation and infarct expansion. However, little information is available regarding their long-term effects on LV remodeling in patients surviving Q-wave AMI.

METHODS AND RESULTS

This was a randomized, double-blind, placebo-controlled trial designed to investigate the long-term (6-month) efficacy of intermittent transdermal nitroglycerin (NTG) patches on LV remodeling in 291 survivors of AMI. Patients meeting entry criteria had baseline gated radionuclide angiography (RNA) followed by randomization to placebo or active NTG patches delivering 0.4-, 0.8-, or 1.6-mg/h. RNA was repeated at 6 months and 6.5 days after withdrawal of double-blind medication. The primary study end point was the change in end-systolic volume index (ESVI). Both ESVI and end-diastolic volume index (EDVI) were significantly reduced with 0.4-mg/h NTG patches (-11.4 and -11.6 mL/m2, respectively, P<.03). This beneficial effect was observed primarily in patients with a baseline LV ejection fraction < or =40% (deltaESVI, -31 mL/m2; deltaEDVI, -33 mL/m2; both P<.05) and only at the 0.4-mg/h dose. After NTG patch withdrawal, ESVI significantly increased but did not reach pretreatment values.

CONCLUSIONS

Transdermal NTG patches prevent LV dilation in patients surviving AMI. The beneficial effects are limited to patients with depressed LV function and only at the lowest (0.4-mg/h) dose. Continued administration is necessary to maintain efficacy. Whether these remodeling effects confer a clinical or survival advantage will need to be addressed in an adequately powered cardiac event trial.

Design of a randomized, placebo-controlled multicenter trial on the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction. Transdermal Nitroglycerin Investigators Group

Nitrates are widely used in the treatment of patients with ischemic heart disease and in those with angina following acute myocardial infarction. Short-term studies indicate that the administration of nitrates may prevent left ventricular (LV) dilation and infarct expansion. Animal models suggest that prolonged nitroglycerin use after infarction may limit LV remodeling similar to that observed with angiotensin-converting enzyme inhibitors. However, to date there have been no trials evaluating the effects of nitrates on LV volumes in patients surviving acute myocardial infarction. We therefore performed a randomized double-blind, placebo-controlled trial designed to investigate the long-term (6 month) efficacy of intermittent transdermal nitroglycerin patches on LV remodeling in 291 survivors of acute myocardial infarction. Patients were randomized to receive either placebo or a nitroglycerin patch that delivered 0.4, 0.8, or 1.6 mg/hour. Gated radionuclide angiography was used to assess serial changes in LV ejection and cardiac volumes. The baseline characteristics of the study population were similar in all 4 treatment groups. The study protocol and the main design-related issues are described.

Worsening left ventricular performance on serial exercise radionuclide angiography does not identify high-risk patients

OBJECTIVE

To determine whether worsening exercise performance on serial exercise radionuclide angiography identifies patients at increased risk of future cardiac events.

MATERIAL AND METHODS

One hundred nine medically treated patients with previous Q-wave myocardial infarction underwent two exercise radionuclide angiographic studies at least 6 months apart (median, 16 months) without an intervening clinical event. Worsening exercise performance between the two studies was defined by five criteria: (1) lower (5% or more) peak exercise ejection fraction; (2) worsening peak exercise wall motion score; (3) combination of criteria 1 and 2; (4) worsening serial delta (exercise - rest) ejection fraction; or (5) increasing exercise ST-segment depression of 1 mm or more. Patients were followed up for a median duration of 3.9 years after the second exercise study.

RESULTS

Five cardiac deaths and 10 nonfatal myocardial infarctions occurred during follow-up. A Cox proportional hazards analysis failed to show an association between any of the aforementioned variables and cardiac events. Of the 15 patients with cardiac events, 4 (27%) had a lower (5% or more) exercise ejection fraction and 2 (13%) had a worsening exercise wall motion score. Of the 94 patients without cardiac events, 37 (39%) had a lower (5% or more) exercise ejection fraction and 28 (30%) had a worsening serial exercise wall motion score (not a statistically significant difference).

CONCLUSION

Worsening exercise performance on serial exercise radionuclide angiography does not identify patients at increased risk of future cardiac events.

Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity

Amiodarone in doses of 200 to 400 mg/day has shown promise in secondary prevention trials for reducing mortality in patients surviving myocardial infarction who have complex ventricular ectopy or nonsustained ventricular tachycardia, or both. In an attempt to explore the lowest dose of amiodarone with antiarrhythmic and hemodynamic activity, we studied 48 patients (mean age 53 +/- 11 years, ejection fraction 23 +/- 9%, clinical heart failure in 85%) with nonsustained ventricular tachycardia. This was a 3-month, randomized, parallel, double-blind pilot study comparing placebo (n = 16) with amiodarone 50 mg/day (n = 15) and 100 mg/day (n = 17). Patients randomized to amiodarone received a mean loading dose of 422 mg/day for the first study week. At the end of the 12 weeks, amiodarone (100 mg) significantly reduced ventricular premature complexes (177 +/- 64 to 98 +/- 38/hour), couplets (8 +/- 3 to 4 +/- 2/hour), and runs of nonsustained ventricular tachycardia (13 +/- 7 to 3 +/- 2/day), all p < 0.01 versus baseline. In addition, 10 of 14 patients taking 100 mg/day had total suppression of nonsustained ventricular tachycardia compared with 4 of 15 taking placebo, p = 0.021. Left ventricular ejection fraction improved by > or = 7% (absolute) in 11 of 29 patients taking amiodarone as compared with only 1 of 15 placebo patients (p = 0.02). In these 11 patients with the greatest measurable hemodynamic improvement, amiodarone significantly increased ejection fraction (21 +/- 7% to 33 +/- 11%, p < 0.01), stroke volume index (28 +/- 9 to 40 +/- 7 ml/m2, p < 0.01) and decreased end-systolic volume index (116 +/- 48 to 92 +/- 44 ml/m2, p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Spontaneous variability of ventricular function in patients with chronic heart failure. The Western Enoximone Study Group and the REFLECT Investigators

PURPOSE

The spontaneous variation of the left and right ventricular ejection fractions (LVEF and RVEF) was evaluated in patients with chronic heart failure receiving only digoxin and diuretics over a 12-week interval.

PATIENTS AND METHODS

Fifty-one patients with stable heart failure were studied with radionuclide angiography. A baseline evaluation and a 12-week follow-up study were performed. Heart failure therapy consisted of digoxin and diuretics alone during this time.

RESULTS

The mean baseline LVEF (n = 51) was 27.2 +/- 9.5 (range: 7 to 50) and the LVEF after 12 weeks was 27.6 +/- 9.7 (range: 11 to 53; p = NS versus baseline). Mean RVEF (n = 19) was 31.9 +/- 11.3 at baseline and 30.3 +/- 11.3 (range: 14 to 50; p = NS versus baseline) after 12 weeks. Although there was no significant change in mean LVEF or RVEF in this group of patients, individual patients demonstrated considerable spontaneous variation. Individual LVEF values changed from 0 to 26 ejection fraction percentage points (mean of individual changes = 5.6 +/- 5.5). Individual RVEF determinations over the 12-week period varied by 0 to 15 percentage units (mean = 5.6 +/- 4.9). Thirty-five percent of patients had an absolute change in LVEF greater than 5 and 37% of patients had an absolute change of RVEF greater than 5. Even after deletion of the two worst outliers from the LVEF and RVEF data, a change in LVEF greater than 13 and a change in RVEF greater than 11% units were necessary to exclude spontaneous variation as a likely cause for the observed changes (95% confidence limits). No relationship between a change in the individual patient's LVEF or RVEF was found when these values were compared with exercise time, systolic or diastolic blood pressure, heart rate, or degree of baseline left or right ventricular dysfunction.

CONCLUSION

In patients with heart failure, large (greater than 5) spontaneous changes in LVEF and RVEF may be seen in over one third of patients during a 12-week period. This variability should be considered when the ejection fraction is used as an index of improved or worsened cardiac function. The use of the LVEF and RVEF to assess interventions or therapy for heart failure should be interpreted with caution.

Novel approach to the interpretation of long-term "deterioration" in ejection fraction in individual patients with coronary artery disease

OBJECTIVE

The long-term predictability of left ventricular ejection fraction (LVEF) measurements was evaluated with particular emphasis on the assessment of deterioration in individual patients whose coronary artery disease was initially treated medically.

DESIGN

Prospective pilot study.

SETTING

Regional cardiac centre.

PATIENTS

60 minimally symptomatic patients with coronary artery disease who, after arteriography, were initially treated medically.

INTERVENTION

Measurement of LVEF by first pass exercise radionuclide ventriculography at baseline and six months later without interruption of usual anti-ischaemic medication. Baseline and six-month studies were analysed independently of each other.

MAIN OUTCOME MEASURE

Based on 51 patients who remained event free, 95% prediction intervals were derived for prognostic LVEF indices to suggest the minimum change from baseline that might be considered clinically important in the individual patient, alerting clinicians to the need for closer review.

RESULTS

At six-month ventriculography, 22 patients showed apparent deterioration in exercise LVEF or the change in LVEF with exercise (delta LVEF). Only two patients had six-month values below the lower limit of 95% prediction intervals, compared with 15 when 95% group confidence intervals (z = 3.33, p < 0.001) were used. When delta LVEF = 0 at baseline, the lower limit of 95% prediction intervals allowed for an exercise induced fall at six months of < or = 13%. For a baseline exercise LVEF of 50% (just normal), the lower limit of 95% prediction intervals was 38%--that is, the exercise LVEF could be measured as low as 38% > or = six months later without necessarily indicating or missing true deterioration.

CONCLUSION

In the follow up of minimally symptomatic patients with coronary artery disease, serial long-term changes, in particular "deterioration," in prognostic LVEF indices may be interpreted more meaningfully with reference to 95% prediction intervals.

Efficacy and safety of sotalol in patients with complex ventricular arrhythmias

Sotalol is a unique beta-blocker that prolongs repolarization. Its use in 626 patients with complex ventricular ectopic activity, as reported in the literature, resulted in suppression of arrhythmia in 50 to 60% of treatment attempts. Detailed analysis of data on arrhythmias in 356 patients that were entered prospectively into a database revealed a median reduction in ventricular premature beats of 76%, compared to a median suppression of repetitive ventricular ectopic activity of 91% and of episodes of nonsustained ventricular tachycardia of 97% (p = 0.002 vs reduction of ventricular premature beats). This marked antiarrhythmic potency of sotalol in repetitive ventricular arrhythmias is thought to be due to its class III activity. Drug efficacy was independent of age, sex, the presence or absence of organic heart disease and the degree of sotalol-induced prolongation of corrected QT interval. Evaluation of left ventricular function in 215 patients treated with the drug demonstrated that depression of left ventricular ejection fraction occurred far less frequently than expected with conventional beta-blockers. Even patients with severely depressed pump function tolerated sotalol surprisingly well. There is a propensity of the drug to aggravate arrhythmia, which resulted in serious proarrhythmic events in 30 (3.5%) of 853 patients. These often consisted of torsades de pointes (9 of 30 patients). Proarrhythmia occurred primarily within the first 3 days of dosing, and exhibited a dose-dependence. In conclusion, sotalol is an effective and well-tolerated antiarrhythmic drug in patients with complex ventricular ectopic activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint

Clinical trials often involve a variety of clinical and laboratory measures that are used as endpoints and sometimes two of these measures are combined in one endpoint. When the individual components of such a combined endpoint are 'time to event' measurements, the analysis is straightforward if each of the components is measured frequently and regularly over time. However, the analysis of the combined endpoint is more difficult when one component of the endpoint is right censored and the other is interval censored. This paper describes a statistic, based on a rank ordering of events for such a combined measure. The power of the test statistic is explored.